Published phase 1 studies reported that patients with metastatic BC, who incorporated anti–PD-L1 antibody atezolizumab or avelumab, had a higher objective response rate (ORR) and a longer overall survival (OS) when TILs positively expressed PD-L1 [15, 21]. The gene discussed is CD274; the disease is breast cancer.